Home

Qure.ai Recognized Among TIME’s 100 Most Influential Companies of 2025

via Business Wire

Recognized as a pioneer on the TIME100 Most Influential Companies list, Qure.ai is using AI to reshape access and diagnosis of high-burden diseases worldwide.

Qure.ai, the world’s most widely adopted digital health innovator, has been named to TIME’s 2025 TIME100 Most Influential Companies list. Now in its fifth year, the TIME100 list highlights companies making an extraordinary global impact through innovation, ambition, and measurable success.

TIME’s editorial spotlighted Qure.ai’s work in advancing diagnostic equity through AI, stating: “Trained on one of the world’s largest data sets, Qure.ai’s algorithms are as accurate as a radiologist, according to the company, providing crucial insights in rural or developing areas where specialists may not be available. Qure.ai tools have now been deployed in more than 100 countries, and the company has 18 FDA clearances—the greatest number for lung cancer AI in the U.S.—including three new approvals in 2024.”

Qure.ai was selected alongside iconic and dynamic brands such as Abbott, Midi Health, Vertex Pharmaceuticals, Function Health, Gilead, CRISPR Therapeutics, NBBJ, and Northwell Health, and is featured in the Pioneer category among health tech AI firms on the 2025 list.

Speaking on the recognition, Prashant Warier, CEO and Founder said, “To be named among TIME’s 100 Most Influential Companies is an acknowledgment of a simple but urgent belief: that access to timely, high-quality diagnostics should not depend on where you live. This honor reflects the dedication of our teams and partners across continents, working to close the gap between innovation and impact. This recognition pushes us to keep advancing that future, where care begins long before crisis.”

This milestone recognition follows a pivotal year for Qure.ai, marked by accelerated momentum in the United States. With over 18 FDA-cleared findings and the launch of its Lung Cancer Care Continuum, a portfolio of AI solutions to detect, measure, and manage lung nodules; Qure.ai now offers an end-to-end suite that supports earlier lung cancer diagnosis across diverse care settings. Backed by a strategic Series D round led by global investors including Lightspeed, 360 One Asset, and the Merck Global Health Innovation Fund, the company is scaling its commercial and clinical impact worldwide.

On the global front, Qure.ai continues to lead in innovation for low- and middle-income countries, drawing on its deep experience in TB surveillance at scale. Its newest offering, Aira, a multi-disease clinical AI co-pilot, was launched at the World Health Assembly in Geneva to support care coordination in resource-constrained settings.

To compile this year’s TIME100 list, TIME’s editors evaluated nominees across sectors based on impact, innovation, ambition, and success, after polling its global network of journalists and outside experts. The final list spotlights 105 companies helping chart a path forward for the world.

See the full list here: https://time.com/collections/time100-companies-2025/7289652/qure-ai/?filters=pioneers

About Qure.ai

Qure.ai is a health tech company that uses deep learning and Artificial Intelligence (AI) to make healthcare more accessible and equitable for patients worldwide. Our solutions power the efficient identification and management of Tuberculosis (TB), Lung Cancer and Neurocritical conditions to support clinicians and propel developments in the pharmaceutical and medical device industries. We empower healthcare by helping to identify conditions fast, prioritize treatment planning and ultimately improve quality of patient life.

Contacts